The Treatment of @entity12347 and @entity2805 with intralesional XXXX in skin of color.

@entity1 @entity12347 @entity2995 @entity2117 @entity228 @entity2805 @entity1732 @entity272 @entity2713
UNASSIGNED: Intralesional injection with @entity228 remains the mainstay of therapy for @entity2805 and @entity12347 , however some lesions are unresponsive or may result in @entity272 . Intralesional @entity1732 injection is an alternative therapy that has been widely reported. In order to compare the effectiveness and safety of @entity1732 for the treatment of @entity12347 and @entity2805 in skin of color population, Fitzpatrick skin type III to V @entity1 with @entity12347 or @entity2805 were randomized into two groups. Group A was treated monthly with intralesional @entity2995 (10  mg/mL), while group B with intralesional @entity1732 (1  mg/mL) for three consecutive months. Evaluation of the treatment was performed using " @entity1 and Observer Scar Assessment Scale" (POSAS), self-rated @entity1 satisfaction score, photography, and ultrasonography. Two @entity1 had their @entity1732 blood levels monitored. Twenty-six @entity1 with @entity12347 or @entity2805 were recruited. The clinical improvement as assessed by the POSAS was not statistically significant. In terms of @entity1 satisfaction score, one half of both groups reported a very good improvement. Photographic as well as ultrasonographic evaluation showed no difference between the two groups. @entity1732 was found to enter the blood circulation in a very small amount. The major side effect was @entity2117 . There was no @entity272 detected in this study. Intralesional @entity1732 is a safe and effective treatment for @entity12347 and @entity2805 . The treatment is comparable to intralesional @entity2713 . Unfortunately, @entity2117 was the major side effect in darker skin type.
